Prostate brachytherapy post-implant dosimetry: A comparison between higher and lower source density

Radiotherapy and Oncology

Volumn 83, Issue 1, 2007, Pages 18-24

  Thomas, Carys W ^a   Kruk, Alexandra ^a   McGahan, Colleen E ^b   Spadinger, Ingrid ^c   Morris, W James ^a  

^a Department of Radiation Oncology ^*

^b Surveillance and Outcomes Unit

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Post implant dosimetry; Prostate brachytherapy; Source strength

Indexed keywords

ARTICLE; BRACHYTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DOSIMETRY; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RECTUM; URETHRA;

BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; PROSTATE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; URETHRA;

EID: 34047256721     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.02.004     Document Type: Article

References (26)

1. Ash D., Al-Qaisieh B., Bottomley D., Carey B., and Joseph J. The correlation between D90 and outcome for I-125 seed implant monotherapy for localized prostate cancer. Radiother Oncol 79 (2006) 185-189
2. Bice Jr. W.S., Prestidge B.R., Grimm P.D., et al. Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 41 (1998) 921-927
3. Bland J.M., and Altman D.G. Measurement error. BMJ 313 (1996) 744
4. Bucci J., Morris W.J., Keyes M., Spadinger I., Sidhu S., and Moravan V. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 53 (2002) 91-98
5. Bucci J., Spadinger I., Hilts M., et al. Urethral and periurethral dosimetry in prostate brachytherapy: is there a convenient surrogate?. Int J Radiat Oncol Biol Phys 54 (2002) 1235-1242
6. D'Souza W.D., and Meyer R.R. Dose homogeneity as a function of source activity in optimized I-125 prostate implant treatment plans. Int J Radiat Oncol Biol Phys 51 (2001) 1120-1130
7. Dubois D.F., Prestidge B.R., Hotchkiss L.A., Prete J.J., and Bice Jr. W.S. Intraobserver and interobserver variability of MR imaging- and CT-derived prostate volumes after transperineal interstitial permanent prostate brachytherapy. Radiology 207 (1998) 785-789
8. Grimm P.D., Blasko J.C., Sylvester J.E., Meier R.E., and Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2002) 31-40
9. Han B.H., Wallner K., Merrick G., Badiozamani K., and Butler W. The effect of interoserver differences in post implant prostate CT image interpretation on dosimetric parameters. Med Phys 30 (2003) 1096-1102
10. Keyes M., Schellenberg D., Moravan V., et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve?. Int J Radiat Oncol Biol Phys 64 (2006) 825-834
11. Lee W.R., Roach III M., Michalski J., Moran B., and Beyer D. Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. Int J Radiat Oncol Biol Phys 54 (2002) 457-461
12. Lindsay P.E., Van Dyk J., and Battista J.J. A systematic study of imaging uncertainties and their impact on I-125 prostate brachytherapy dose evaluation. Med Phys 30 (2003) 1897-1908
13. Macdonald A.G., Keyes M., Kruk A., Duncan G., Moravan V., and Morris W.J. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: is dose to the penile bulb important?. Int J Radiat Oncol Biol Phys 63 (2005) 155-163
14. Maguire P.D., Waterman F.M., and Dicker A.P. Can the cost of permanent prostate implants be reduced? An argument for peripheral loading with higher strength seeds. Tech Urol 6 (2000) 85-88
15. McLaughlin P.W., Narayana V., Drake D.G., et al. Comparison of MRI pulse sequences in defining prostate volume after permanent implantation. Int J Radiat Oncol Biol Phys 54 (2002) 703-711
16. McLaughlin P.W., Narayana V., Fields M.T., Dworzanin M.E., Winfield R.J., and Roberson P.L. Permanent implantation of 125I sources in the prostate: radical limits of simplicity. Radiology 213 (1999) 839-844
17. Morris J.M., Keyes M., McKenzie M., et al. The five-year relapse-free and overall survival following permanent 124 Iodine prostate brachytherapy. Radiother Oncol 80 (2006) S42
18. Narayana V., Troyer S., Evans V., Winfield R.J., Roberson P.L., and McLaughlin P.W. Randomized trial of high- and low-source strength (125)I prostate seed implants. Int J Radiat Oncol Biol Phys 61 (2005) 44-51
19. Potters L., Cao Y., Calugaru E., Torre T., Fearn P., and Wang X.H. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 50 (2001) 605-614
20. Cary NC, SAS/STAT User's Guide, Version 6, 4th ed., vols. 1 and 2: SAS Institute Inc.; 1989.
21. Sidhu S., Morris W.J., Spadinger I., et al. Prostate brachytherapy postimplant dosimetry: a comparison of prostate quadrants. Int J Radiat Oncol Biol Phys 52 (2002) 544-552
22. 125I seeds in inverse-planned prostate implants?. Int J Radiat Oncol Biol Phys 55 (2003) 234-244
23. Sloboda R.S., Pedersen J.E., Hanson J., and Halperin R.M. Dosimetric consequences of increased seed strength for I-125 prostate implants. Radiother Oncol 68 (2003) 295-297
24. Spadinger I, Hilts M, Keyes M, Smith C, Sidhu S, Morris WJ. Prostate brachytherapy post-implant dosimetry: a comparison of suture embedded and loose seed implants. Brachytherapy; in press.
25. Stock R.G., Stone N.N., Tabert A., Iannuzzi C., and DeWyngaert J.K. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
26. Vikram B., Deore S., Beitler J.J., et al. The relationship between dose heterogeneity ("hot" spots) and complications following high-dose rate brachytherapy. Int J Radiat Oncol Biol Phys 43 (1999) 983-987